PeptideMark

Mechanism of Action

Lipolytic GH Fragment Activity

Growth hormone C-terminal fragment that selectively promotes lipolysis without the anabolic effects of full-length GH.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Compounds

1

Total studies

23

Human studies

2

FDA approved

0

Overview

AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone (residues 176-191). This fragment retains the lipolytic (fat-burning) activity of full-length GH but lacks the anabolic / diabetogenic effects mediated by the N-terminus. It was investigated as a weight loss agent and for osteoarthritis.

AOD-9604 is a synthetic fragment of residues 176-191 of human growth hormone — the C-terminal lipolytic domain. The rationale for its development was mechanism separation: the N-terminal region of GH drives the anabolic and diabetogenic effects (via IGF-1 mediation), while the C-terminal fragment retains lipolytic activity. In preclinical models, AOD-9604 activates hormone-sensitive lipase and promotes fat oxidation without affecting IGF-1 or glucose tolerance. Phase 2 human trials for weight loss, however, failed to show meaningful efficacy versus placebo.

Receptor & signaling detail

AOD-9604's precise receptor target is not clearly established. The parent growth hormone binds the GH receptor (JAK2/STAT5 pathway), but AOD-9604 does not activate this pathway — suggesting a distinct mechanism for its lipolytic action.

How it works

  1. 1Mimics the lipolytic domain of full-length GH.
  2. 2Activates hormone-sensitive lipase in adipocytes.
  3. 3Promotes release of free fatty acids from fat stores.
  4. 4Does not activate IGF-1 or induce insulin resistance.
  5. 5May support cartilage repair (preclinical).

Downstream clinical effects

  • Increased fat oxidation
  • Reduced fat mass (Phase II pilot data)
  • No measurable impact on glucose tolerance
  • Potential cartilage / joint benefits

Documented clinical implications

  • No measurable effect on IGF-1 or glucose tolerance
  • Preclinical models show increased lipolysis
  • Phase 2 weight-loss data was underwhelming vs placebo
  • Potential investigation for osteoarthritis (cartilage effects)

Limitations & mechanism-driven side effects

  • Phase 2 weight-loss data largely negative
  • Not FDA approved
  • Often marketed beyond what the data supports
  • Mechanism of action remains partially characterized

Discovery & development

AOD-9604 was developed at Monash University in Australia in the 1990s. It received TGA (Australian regulatory) "generally recognized as safe" status as a food supplement but has not received FDA approval for any indication.

Peptides using this mechanism

AOD-9604

A modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full GH.

L2Research Only23 studies
AOD-9604 legal status →AOD-9604 research timeline →

Evidence status

Phase II human trials exist; not FDA approved. Safety profile is favorable in trials.

Frequently asked questions

Does AOD-9604 really cause weight loss?

Phase 2 human trials did not demonstrate significant weight loss versus placebo. Marketing claims often exceed the actual trial evidence.

Is AOD-9604 safer than HGH?

AOD-9604 does not raise IGF-1 or affect glucose tolerance — suggesting a more benign metabolic profile than exogenous HGH. Whether this translates to meaningful safety benefit in practice is less clear.

Can AOD-9604 help osteoarthritis?

Preclinical cartilage data is suggestive but human clinical evidence is thin. Not an approved therapy for osteoarthritis.

Is AOD-9604 legal?

It is not FDA approved for any indication in the United States. Australia granted a food-supplement status but this does not extend internationally.

Relevant best-of guides

Best Peptides for Weight Loss: Evidence-Based Ranking

Peptides with the strongest published weight-loss outcomes — ranked by trial quality and FDA regulatory standing.

Related articles

AOD-9604 vs Semaglutide: Fat Loss Peptides Compared

Comparison · 8 min

MOTS-c vs AOD-9604: Metabolic Peptides Compared

Comparison · 5 min

Semaglutide vs AOD-9604: Weight Loss Evidence Gap

Comparison · 5 min

Retatrutide vs AOD-9604: Next-Gen vs Legacy Weight Loss

Comparison · 5 min

Best Peptides for Fat Loss: Complete Evidence Ranking 2026

Guide · 10 min

Related mechanism comparisons

GHRH Receptor Agonism vs Lipolytic GH Fragment Activity

Pathway, evidence, and compound comparison

Ghrelin Receptor Agonism vs Lipolytic GH Fragment Activity

Pathway, evidence, and compound comparison

GLP-1 Receptor Agonism vs Lipolytic GH Fragment Activity

Pathway, evidence, and compound comparison